Summit Therapeutics established a clinical trial collaboration with Pfizer to develop ivonescimab for NSCLC and solid tumors.

We recently published a list of 10 Stocks Drop The Most Amid Investor Caution. In this article, we are going to take a look ...

The partners will test Summit’s ivonescimab alongside Pfizer’s antibody-drug conjugates in hopes of finding “potentially ...

Pfizer has partnered with Summit Therapeutics to evaluate ivonescimab, a PD-1/VEGF bispecific antibody, in combination with ...

SMMT's Q4 results meet estimates. The company signs a deal with Pfizer that expands ivonescimab's development beyond the NSCLC indication.

Pfizer partners with Summit Therapeutics to advance cancer treatments using ADCs and ivonescimab. Click here to find out why ...

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that its partner on ivonescimab, Summit Therapeutics Inc. (NASDAQ: SMMT) has entered into a clinical trial collaboration with Pfizer ...

Florida, USA-based Summit Therapeutics saw its share rise 6.2% to $23.50 pre-market on the news of a clinical trial ...

Pfizer has signed a deal with Summit Therapeutics to assess the efficacy of Summit’s ivonescimab in combination with several ...

Summit Therapeutics sank -13.4% today, compared to the S&P 500's day change of -0.0%. Today's losers may turn out to be ...

Summit Therapeutics shares are dropping Monday morning as it reported a fourth-quarter adjusted loss nearly double that of the prior year. It also announced a collaboration with Pfizer.